Close this search box.

Clinical Trial: SWOG S1929

SWOG S1929

Status: Closed

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

S1929 is permanently closed to accrual on December 15, 2022, at 12pm Pacific Time.